Last $15.13 USD
Change Today +0.13 / 0.87%
Volume 39.3K
TKAI On Other Exchanges
As of 8:10 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

tokai pharmaceuticals inc (TKAI) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/17/14 - $30.00
52 Week Low
10/10/14 - $9.67
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

tokai pharmaceuticals inc (TKAI) Related Businessweek News

No Related Businessweek News Found

tokai pharmaceuticals inc (TKAI) Details

Tokai Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel proprietary therapies for the treatment of prostate cancer and other hormonally-driven diseases in the United States. Its lead drug candidate includes galeterone, an oral small molecule drug candidate, which is in Phase II clinical trials for the treatment of castration resistant prostate cancer. The company was founded in 2004 and is headquartered in Cambridge, Massachusetts.

14 Employees
Last Reported Date: 09/18/14
Founded in 2004

tokai pharmaceuticals inc (TKAI) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $422.0K
Compensation as of Fiscal Year 2013.

tokai pharmaceuticals inc (TKAI) Key Developments

Tokai Pharmaceuticals Obtains Exclusive, Worldwide License from the Johns Hopkins University

Tokai Pharmaceuticals reported that it has entered into an agreement with the Johns Hopkins University related to the development of a companion diagnostic to determine the AR-V7 status of patients with castration-resistant prostate cancer (CRPC) for use with the Company's lead product, galeterone, which is in development for the treatment of AR-V7 positive metastatic CRPC. Under the agreement, the Company has obtained an exclusive, worldwide license from the Johns Hopkins University to patent applications and know-how covering an assay that has been used to determine the AR-V7 status of prostate cancer patients.

Tokai Pharmaceuticals, Inc. Appoints Stephen Buckley, Jr. to the Board of Directors and as Chair of the Audit Committee

Tokai Pharmaceuticals, Inc. announced that Stephen Buckley, Jr. has joined the company’s board of directors and will serve as chair of the audit committee. Mr. Buckley spent 25 years as a partner of Ernst & Young LLP, where he led assurance and advisory teams serving public and private companies in life sciences and other technologies. Mr. Buckley ran Ernst & Young’s Life Sciences Industry Practice of New England from 1991 to 2006, and was director of its New England Entrepreneurial Services Group from 1991 to 2001. He was previously a partner in the Boston, Massachusetts office of Arthur Young until its merger into Ernst & Young in 1989.

Tokai Pharmaceuticals, Inc.(NasdaqGM:TKAI) added to Russell 2000 Index

Tokai Pharmaceuticals, Inc. will be added to the Russell 2000 Index.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TKAI:US $15.13 USD +0.13

TKAI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TKAI.
View Industry Companies

Industry Analysis


Industry Average

Valuation TKAI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 3.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TOKAI PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at